Searchable abstracts of presentations at key conferences in endocrinology

ea0030oc5.1 | Oral Communications 5 | BSPED2012

Adolescent transition clinic: a review of the young person's self-confidence and future concerns

Whitehead A , Walker J , Mushtaq T , Alvi N S

Introduction: There has been a joint transition clinic in our tertiary centre for over 10 years. We have recently undertaken a questionnaire based review of this service.Methodology: The questionnaire comprised two components: what the young adults understood about their condition and the medications they were currently taking using both a written response and a score of 0–10 for how confident they felt in this. They were also asked to complete a co...

ea0024p8 | (1) | BSPED2010

Comparison of the low dose synacthen and glucagon stimulation tests in the assessment of adrenal function in children with short stature

Peacock A , Mushtaq T , Alvi N S , Barth J

Introduction: The 1 μg low dose short Synacthen tests (LDSST) and the glucagon stimulation tests (GST) have been suggested to be safer alternatives to the insulin induced hypoglycaemia stress test. The aim of this study was to compare the peak plasma cortisol concentration in response to a LDSST followed 60 min later by a GST in children undergoing investigation for short stature.Methods: We retrospectively studied 38 patients (19 female, 19 male) w...

ea0030oc5.3 | Oral Communications 5 | BSPED2012

A comparison of patient's preferences for attributes of GH delivery devices: children starting versus children established on GH treatment

Yaw Stephanie How , Mushtaq Talat , Alvi N S , Walker Jenny , Whitehead Amanda

Background: Several devices are available for the administration of recombinant GH. A prospective study was undertaken to look at those attributes of GH delivery device most important to patients when making their choice.Objectives: i) To understand which features of a GH device are considered most important to patients when choosing a device. ii) Comparison of patient’s device preferences at start of GH treatment and after 2 years of treatment. iii...